Related Experiment Videos
Cyanosis, cough, and hypotension following intravenous administration of paraldehyde
Pediatrics
|January 1, 1976
Insights
Intravenous administration of paraldehyde can cause pulmonary edema in children. Undiluted paraldehyde given intravenously poses significant hazards, requiring caution in pediatric care.
Area of Science:
- Pediatric Medicine
- Pharmacology
- Critical Care
Background:
- Paraldehyde is a sedative-hypnotic historically used for various conditions.
- Intravenous administration routes require careful consideration due to potential toxicity.
- Pulmonary edema is a serious condition characterized by fluid accumulation in the lungs.
Observation:
- A pediatric case study documented the development of pulmonary edema.
- The adverse event occurred subsequent to the intravenous administration of paraldehyde.
- Roentgenographic evidence confirmed the presence of lung fluid accumulation.
Findings:
- Intravenous paraldehyde administration in a child led to clinical and roentgenographic signs of pulmonary edema.
- Experimental data supports the hazardous nature of undiluted intravenous paraldehyde.
- The findings highlight a critical risk associated with this route of administration.
Implications:
- Clinicians should exercise extreme caution when considering intravenous paraldehyde, especially in pediatric patients.
- Alternative sedative or hypnotic agents may be preferable to avoid this severe adverse event.
- Further research into safer paraldehyde formulations or administration methods is warranted.
Abstract:
Clinical and roentgenorgraphic evidence of pulmonary edema developed following the intravenous administration of paraldehyde to a child. Experimental and clinical evidence indicate that administration of undiluted paraldehyde intravenously is hazardous.